Indications of immune protection from hepatitis C infection.

Aitken CK, Bowden S, Hellard M, Crofts N.
J Urban Health 2004; 81:58-60.

Change in hepatitis C virus genotype in injecting drug users.

Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, Crofts N, Hellard M.
J Med Virol 2004; 74:543-554.

Molecular epidemiology of hepatitis C virus in a social network of injection drug users.

Aitken CK, McCaw RF, Bowden DS, Tracy SL, Kelsall JG, Higgs PG, Kerger MJ, Nguyen H, Crofts JN.
J Infect Dis 2004; 190:1586-1595.

Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it’s time to get off!

Angus P, Locarnini S.
Antiviral Therapy 2004; 9:145-148.

HBV genotyping and analysis for unique mutations.

Ayres A, Locarnini S, Bartholomeusz A.
Methods Mol Med 2004; 96:125-149.

Hepatitis B virus genotypes: comparison of genotyping methods.

Bartholomeusz A, Schaefer S.
Rev Med Virol 2004; 14:3-16.

Comparisons of the HBV and HIV polymerase and antiviral resistance mutations.

Bartholomeusz A, Tehan B, Chalmers D.
Antiviral Therapy 2004; 9:149-160.

Prevalence of HBsAg mutants and impact of hepatitis B infant immunization in Four Pacific Island countries.

Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF.
Vaccine 2004; 22:2791-2799.

Monitoring gene expression using DNA microarrays during hepatitis infection.

Beard MR, Locarnini S.
Methods Mol Med 2004; 96:55-64.

Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR.

Bowden S, Jackson K, Littlejohn M, Locarnini S.
Methods Mol Med 2004; 95:41-50.

Annual report of the Australian National Poliovirus Reference Laboratory, 2003.

Brussen KA, Stambos V, Thorley BR.
Commun Dis Intell 2004; 28:339-344.

Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus.

Chibo D, Druce D, Sasadeusz J, Birch C.
Antiviral Research 2004; 61:83-91.

Validation of assembled nucleic acid-based tests in diagnostic microbiology laboratories.

Dimech W, Bowden DS, Brestvac B, Byron K, James G, Jardine D, Sloots T, Dax EM.
Pathology 2004; 36:45-50.

An outbreak of shigellosis in a child care centre.

Genobile D, Gatson J, Tallis GF, Gregory JE, Griffith JM, Vulcanis M, Lightfoot D, Marshall JA.
Commun Dis Intell 2004; 28:225-229

MIRU: the national tuberculosis genotyping strategy in Australia.

Gilpin C, Fyfe J.
Microbiology Australia 2004; 25:34-35.

Studying the treatment of chronic hepatitis B viral infection in special populations.

Gish R, Locarnini S.
Methods Mol Med 2004; 96:465-498.

Norovirus excretion in a health-care worker without major symptoms of gastroenteritis: infection control implications.

Goller JL, Dimitriadis A, Kelly H, Marshall JA.
Aust NZ J Public Health 2004; 28:88-89.

Long-term features of norovirus gastroenteritis in the elderly.

Goller JL, Dimitriadis A, Tan A, Kelly H, Marshall JA.
J Hosp Infect 2004; 58:286-291.

An outbreak of Legionnaires' disease at the Melbourne Aquarium, April 2000: investigation and case-control studies.

Greig JE, Carnie JA, Tallis GF, Ryan NJ, Tan AG, Gordon IR, Zwolak B, Leydon JA, Guest CS, Hart WG.
Med J Aust 2004; 180:566-72.

Mumps and rubella: a year of enhanced surveillance and laboratory testing.

Guy R, Andrews R, Kelly H, Leydon J, Riddell M, Lambert S, Catton M.
Epidemiol Infect 2004; 132:391-398.

Influenza A outbreaks in aged-care facilities: staff vaccination and the emerging use of anti-viral therapy.

Guy RJ, Di Natale R, Kelly HA, Tobin S, Robinson P, Tallis G, Hampson AW.
Med J Aust 2004; 180:640-642.

HBV core sequence: definition of genotype-specific variability and correlation with geographic origin.

Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF.
Vaccine 2004; 11:448-501.

Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region.

Jazayeri MS, Basuni AA, Cooksley G, Locarnini S, Carman WF.
J Hepatol 2004; 41:139-146.

Mycobacterium ulcerans: an unwelcome visitor.

Johnson P, Hayman J, Jenkin G, Stinear P, Globan M, Fyfe J.
Microbiology Australia 2004; 25:20-22.

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programs for people aged 65 years and over.

Kelly H, Atta J, Andrews R, Heller D.
Vaccine 2004; 22:2192-2198.

The causes and diagnosis of influenza-like illness.

Kelly H, Birch C.
Aust Fam Phys 2004; 33:305-309.

Interruption of rubella virus transmission in Australia may require vaccination of adult males: evidence from a Victorian sero-survey.

Kelly H, Worth L, Karapanagiotidis T, Riddell M.
Commun Dis Intell 2004; 28:69-73.

The RpoH-mediated stress response in Neisseria gonorrhoae is regulated at the level of activity.

Laskos L, Ryan C, Fyfe J, Davies J.
J Bacteriol 2004; 186:8443-8452.

Human herpesvirus type 8-associated episodic multisystem illness in an HIV-infected patient in the absence of hemophagocytic lymphohistiocytosis.

Lim LL, Druce J, Street AC.
Clin Infect Dis 2004; 38:1640-1641.

Hepatitis B virus: pathogenesis, viral intermediates and viral replication.

Lee J-Y, Locarnini S.
Clin Liver Dis 2004; 8:301-29.

Molecular virology of hepatitis B virus.

Locarnini S.
Semin Liver Dis 2004; 24:S1:3-10.

Management of antiviral resistance in patients with chronic hepatitis B.

Locarnini S, Hatzakis A, Heathcote J, Keeffe E, Liang TJ, Mutimer D, Pawlotsky J-M, Zoulim F.
Antiviral Therapy 2004; 9:679-693

Failure to detect norovirus in a large group of asymptomatic individuals.

Marshall JA, Hellard ME, Sinclair MI, Fairley CK, Cox BJ, Catton MG, Kelly H, Wright P
JPublic Health 2004; 118:230-233.

Asymptomatic carriage of norovirus. A reply to the comments of Duizer et al.

Marshall J, Kelly H, Wright P.
Public Health 2004; 118:456-457.

Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes and HBsAg subtypes.

Norder H, Courouce A-M, Coursaget P, Echevarria JM, Lee S-D, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO.
Intervirology 2004; 47:289-309.

Entecavir for the treatment of chronic hepatitis B.

Shaw T, Locarnini S.
Expert Rev Anti Infect Ther 2004; 2:853-871.

A parsimonious method for screening drug combinations for antihepadnaviral activity using a parametric dose-response surface approach.

Shaw T, Locarnini S.
Methods Mol Med 2004; 96:387-413.

Problems inherent to antiviral therapy.

Shaw T, Locarnini S.
In: Milestones in Drug Therapy. Eds. Colacino JM, Heinz BA. Birkhauser, Basel, Switzerland, 2004.

Hepatitis B.

Shaw T, Locarnini S.
In: Encyclopedia of Gastroenterology. Ed. Johnson L. Elsevier, Amsterdam, the Netherlands, 2004.

Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

Shaw T, Bowden S, Locarnini S.
Gastroenterology 2004; 126:343-347.

Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, Utama A, Tano Y, Arita M, Yoshida H, Yoneyama T, Benegas A, Roesel S, Pallansch M, Kew O, Miyamura T.
J Virol 2004; 13512-13521.

Clinical emergence of entecavir resistant hepatitis B virus requires additional substitutions in prior lamivudine resistant virus.

Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu C, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.
Antimicrobial Agents Chemotherapy 2004; 48:3498-3507.

Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003.

Tran T, Druce J, Catton M, Kelly H, Birch C.
Sexually Transmit Infect 2004; 80:277-279.

Higher than normal seasonal influenza activity in Victoria, 2003.

Turner J, Tran T, Birch C, Kelly H.
Commun Dis Intell 2004; 28:175-180.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F.
Gastroenterology 2004; 126:1750-1758.

Differences by state in notification of cases presenting with acute flacid paralysis since certification of Australia as polio free.

Whitfield K, Kelly H.
J Paed Child Health 2004; 40:466-469.

Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of lamivudine-resistant hepatitis B virus strains.

Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A, Lau D, Locarnini S, Lewin S.
J Clin Microbiol 2004; 42:3809-3812.

Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine.

Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts, SK.
J Clinical Virol 2004; 31:53-57.